These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9132914)

  • 1. [Pharmacology of hypolipidemic agents].
    Féry F; Balasse EO
    Rev Med Brux; 1997 Feb; 18(1):26-31. PubMed ID: 9132914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacologic treatment of dyslipidemias: Analysis of initiation recommendations and drug selection].
    Davidoff P
    Rev Med Chil; 1991 Dec; 119(12):1423-32. PubMed ID: 9723101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
    Ginsberg HN; Stalenhoef AF
    J Cardiovasc Risk; 2003 Apr; 10(2):121-8. PubMed ID: 12668909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic treatment of lipid metabolism disorders].
    Gmiński J
    Wiad Lek; 1996; 49(7-12):173-81. PubMed ID: 9214849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal management of hyperlipidemia in primary prevention of cardiovascular disease.
    Raza JA; Babb JD; Movahed A
    Int J Cardiol; 2004 Dec; 97(3):355-66. PubMed ID: 15561319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperlipidemia: therapeutic principles in clinical practice].
    Müller-Wieland D; Krone W
    Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying and managing patients with hyperlipidemia.
    Clark AB; Holt JM
    Am J Manag Care; 1997 Aug; 3(8):1211-9; quiz 1223-5. PubMed ID: 10170303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
    Van Diest E; Stoffelen E; Wydooghe L; Van Duppen D; Seuntjens L; Van der Stuyft P
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):361-6. PubMed ID: 11257816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of action of hypolipidemic agents].
    Luc G
    Therapie; 2000; 55(6):661-8. PubMed ID: 11234460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Paillard F; Mosnier M
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):121-6. PubMed ID: 18394585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing drug therapy for patients with hyperlipidemia.
    Safeer RS; Lacivita CL
    Am Fam Physician; 2000 Jun; 61(11):3371-82. PubMed ID: 10865931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities among the disadvantaged: variation in lipid management in the Ohio Medicaid program.
    Litaker D; Koroukian S; Frolkis JP; Aron DC
    Prev Med; 2006 Apr; 42(4):313-5. PubMed ID: 16405983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypolipidemic drugs and diabetes mellitus].
    Bláha V; Mistrík E
    Vnitr Lek; 2009 Apr; 55(4):357-62. PubMed ID: 19449750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.